Navigation Links
Ginger Offers Hope In Ovarian Cancer Fight

A recent study conducted by researchers at University of Michigan has showed that ginger can kill cancer cells//, the results of which were presented at the American Association of Cancer Research. Additionally, it was also found to prevent the development of drug resistance, a phenomenon that makes cancers difficult to treat.

This study highlights that a commonly used spice, ginger could be used in the development of a new drug for cancer treatment. More research is needed however, to substantiate the above findings. Previous studies have already established that ginger has anti-inflammatory properties and can ease nausea.

The researchers applied the commercially available ginger powder, dissolved in a solution to ovarian cancer cells, extracted from cancer patients. All the tests done, revealed that ginger was effective in killing cancer cells. The ginger solution was found to induce a two-way death, one apoptosis (programmed cell death) and autophagy (cell death due to self-digestion).

'Most ovarian cancer patients develop recurrent disease that eventually becomes resistant to standard chemotherapy, which is associated with apoptosis. If ginger can cause autophagic cell death in addition to apoptosis, it may circumvent resistance to conventional chemotherapy,' said Rebecca Liu, report author.

This promising research offers a new ray of hope to cancer patients. The distinct advantage of this treatment the relatively low risk of side effects and the ease of administering the spice in the form of a capsule. The researchers have at this juncture pointed out to the fact that the research is very preliminary and have warned about using this technique without extensive testing and approval.

'This study doesn't mean that people should dash down to the supermarket and stockpile ginger. We still don't know whether ginger, in any form, can prevent or treat cancers in animals or people,' warned Henry Scowcroft, of Cancer Res earch UK.


Related medicine news :

1. Ginger to reduce nausea for pregnant women
2. Ginger Found To Reduce Nausea Associated With Chemotherapy
3. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
4. Drug Offers Hope for Alzheimers disease
5. Drug Firm Offers to Donate Smallpox Vaccine
6. fMRI Offers Insight Into An Infants Brain
7. Gel Offers A More Targeted Approach
8. Umbilical Cord Blood Offers Hope For Patients Who Require Bone Marrow Transplants
9. Surgery Offers Better Treatment For Third Degree Piles
10. New Study Offers Hope For Balding Men
11. Gamma Knife Offers New Hope For Trigeminal Neuralgia Patients
Post Your Comments:

(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: